



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

21 March 2012
EMA/CVMP/IWP/180422/2012
Development and evaluation of veterinary medicines

Committee for medicinal products for veterinary use Immunologicals working party

Schmallenberg workshop

Draft agenda 10 April 2012 Room 2A

Chair: Jean-Claude Rouby

Item	Preliminary draft agenda	Initials
1.	Adoption of draft agenda	
2.	Welcome and aims of meeting - Welcome and tour de table - Background and aims of the meeting	JC. Rouby N. Križ
3.	Disease status and policy considerations - An outbreak of Schmallenberg virus in Germany - disease characteristics and epidemiological considerations - The Schmallenberg virus in the Netherlands – Prevalence and serological considerations - Current status of policy considerations at the European Commission	FLI – M. Beer CVI – W. van der Poel EC/EMA - tbd
	Coffee break	
4.	Lessons learnt from AI and BT authorisations - Lessons learnt by the regulator from the authorisations for AI and BT vaccines - Lessons learnt by the industry from the authorisations for AI and BT vaccines - Exchange of views	Tbd – EMA Tbd – IFAH Europe All
	Lunch break	



Item	Preliminary draft agenda	Initials
5.	Individual company presentations - State of vaccine production and issues presented individually by companies currently working on Schmallerberg virus vaccines	
	Tea break	
6.	Conclusions and recommendations	
7.	A.O.B	